FONT-SIZE Plus   Neg

Aeterna Zentaris Says AEZS-136 Showed Synergy, Efficacy In Human Tumor Cells

Aeterna Zentaris Inc. (AEZS, AEZ.TO) said that a poster on its novel orally active anticancer PI3K/Erk 1/2 inhibitor, AEZS-136, showed the compound's unique inhibition and excellent activity against PI3K and Erk signaling pathways, as well as being well tolerated.

According to the company, AEZS-136 was well tolerated and showed dose-dependent inhibition of human colon tumor growth of up to 72% in a Hct116 mouse model.

Aeterna Zentaris noted that the anti-proliferative efficacy of AEZS-136 was evaluated in more than 40 human tumor cell lines including breast, ovary, endometrium, multiple myeloma, lung, melanoma, colon, leukemia and prostate cancer cells. In vitro ADMET properties were also widely assessed, while in vivo pharmacokinetics and anti-tumor efficacy was explored.

Juergen Engel, Aeterna Zentaris' President and CEO, commented, "The preclinical data presented yesterday, confirms that AEZS-136 has a unique advantageous dual PI3K /Erk kinase inhibition profile which could prove to be more efficient than single pathway inhibition. Furthermore, AEZS-136 has shown to be well tolerated.

Following these encouraging preclinical data, we are currently moving this promising compound into the clinical development stage."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Schaeffler AG, the German auto parts maker owned by the Schaeffler family, Thursday set its initial public offering price at 12.50 euros per share. The company raised gross proceeds of about 938 million euros by offering 75 million shares, of which 66 million from Schaeffler AG and the remaining 9... Dick Costolo, who stepped down as CEO of Twitter in June, is taking a bit of a career turn - to Hollywood. The one-time tech darling left Twitter after 5 years at the helm amid Wall Street concerns about the future of the social media giant. Now he will be consulting on story lines for the HBO series Silicon Valley. Formula One is reportedly near a deal that would sell the racing circuit to an investor group that includes the owner of the Miami Dolphins. The Financial Times reports that the purchase price for the racing company is $8.5 billion. According to the paper, Dolphins owner Stephen Ross has reached a hand-shake agreement with CVC, a private equity firm holding a 35.5 percent stake in Formula One.
comments powered by Disqus
Trade AEZS now with 
Follow RTT